Hq Spclt Pharma Company Profile
✉ Email this page to a colleague
What is the competitive landscape for HQ SPCLT PHARMA, and when can generic versions of HQ SPCLT PHARMA drugs launch?
HQ SPCLT PHARMA has ten approved drugs.
There are six US patents protecting HQ SPCLT PHARMA drugs.
There are twelve patent family members on HQ SPCLT PHARMA drugs in nine countries and eighty-five supplementary protection certificates in fourteen countries.
Summary for Hq Spclt Pharma
International Patents: | 12 |
US Patents: | 6 |
Tradenames: | 13 |
Ingredients: | 9 |
NDAs: | 10 |
Drugs and US Patents for Hq Spclt Pharma
Expired US Patents for Hq Spclt Pharma
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Hq Spclt Pharma | PLATINOL-AQ | cisplatin | INJECTABLE;INJECTION | 018057-003 | Jul 18, 1984 | 4,310,515 | See Plans and Pricing |
Hq Spclt Pharma | TAXOL | paclitaxel | INJECTABLE;INJECTION | 020262-001 | Dec 29, 1992 | 6,096,331 | See Plans and Pricing |
Hq Spclt Pharma | CISPLATIN | cisplatin | INJECTABLE;INJECTION | 018057-004 | Nov 8, 1988 | 5,562,925 | See Plans and Pricing |
Hq Spclt Pharma | ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER | esmolol hydrochloride | SOLUTION;INTRAVENOUS | 205703-002 | Apr 7, 2016 | 6,528,540*PED | See Plans and Pricing |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Hq Spclt Pharma Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
China | 105263809 | See Plans and Pricing |
Australia | 2014228155 | See Plans and Pricing |
European Patent Office | 2948379 | See Plans and Pricing |
Argentina | 108806 | See Plans and Pricing |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Hq Spclt Pharma Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2666774 | CA 2020 00037 | Denmark | See Plans and Pricing | PRODUCT NAME: RELEBACTAM, OPTIONALLY IN THE FORM OF THE MONOHYDRATE, IMIPENEM AND CILASTATIN, OPTIONALLY IN THE FORM OF THE SODIUM SALT; REG. NO/DATE: EU/1/19/1420 20200217 |
0717738 | 12/2002 | Austria | See Plans and Pricing | PRODUCT NAME: LINEZOLID; NAT. REGISTRATION NO/DATE: 1-24227 - 1-24230 20011009; FIRST REGISTRATION: GB PL 00032/0259 - PL 00032/0262 20010105 |
0984957 | C300517 | Netherlands | See Plans and Pricing | PRODUCT NAME: ACETYLSALICYLZUUR EN ESOMEPRAZOLMAGNESIUMTRIHYDRAAT; NAT. REGISTRATION NO/DATE: RVG 107516 20110912; FIRST REGISTRATION: 540235954023675402375 2011120812 |
2957286 | CA 2018 00043 | Denmark | See Plans and Pricing | PRODUCT NAME: PATIROMER SORBITEX CALCIUM AND ANY SALTS AND DERIVATIVES THEREOF; REG. NO/DATE: EU/1/17/1179/001-009 20170721 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.